From the many groundbreaking advances at #ADPD2026 I highlight the following presentation tackling the relevance of #copathology in #Alzheimer:
→Using #gantenerumab trial data the Roche team did a retrospective analysis of CSF samples assessing α-synuclein co-pathology
(1/6)
A poster board asking the AD research community "How likely is it that each of the following will help treat Alzheimer's disease?" With stickers placed to indicate votes, the amyloid and tau hypotheses appear to be the top choices.
Crowdsourced insight from the #AlzheimersDisease research community: #ADPD2026 attendees see the amyloid and tau hypotheses as most promising for treatment, followed by mitochondrial dysfunction. What do you think we’re still missing? #endalz @model-ad.bsky.social
Thank you to the #VJDementia and Dr. James Galvin for taking time out of a busy #ADPD2026 to discuss results from our Phase 2 study of #zervimesine in #dementia with Lewy bodies (DLB): lnkd.in/e_9Cw3N2.
#DementiaWithLewyBodies #DLBPsychosis #DementiaSupport #LewyStrong #Hallucinations #Delusions
What stood out during the first two days of #ADPD2026?
Biomarkers, AI, co pathology and a growing sense of progress.
🎧 New podcast out now
pod.fo/e/3c83fe
Colorful illustration of a silhouette with a brain outline against a vibrant background. "Breaking News Dispatch: Alzheimer’s Oral Therapies, Prevention Strategies, and Targeted Treatments Emerge."
#BreakingNews from #ADPD2026: New treatment approaches to address unmet needs for people living with Alzheimer’s.
Read about promising data on a pill-based treatment, risk-reducing lifestyle changes effective a decade later, and other top stories: https://bit.ly/4bRwFSi
If you didn’t have a chance to connect during the meeting or would like to continue the conversation, please reach out, and we can discuss how tissue clearing can accelerate your research!
#ADPD2026
Thank you #ADPD2026 for another excellent meeting. The $CGTX team returned with a renewed excitement about the state of the science and clinical development in neurodegenerative diseases.
#Neurology #ClinicalResearch #BiotechInnovation #DLBpsychosis
Ace en la #ADPD2026 🔬
Nuestro equipo de genética destaca con 3 ponencias orales:
✨ Claudia Olivé
✨ Alejandro Valenzuela
✨ Raquel Puerta
Excelencia científica para descifrar el Alzheimer. 🧠
Info: https://f.mtr.cool/wjihjnewiu 🔗
#SaludCerebral #Investigación
Last week, the Krembil Foundation team attended the annual #ADPD2026 conference in Copenhagen and spent the week learning, connecting, and engaging with the global Alzheimer’s research community!
We can't wait for next year 🤩🧠🔬
Days after presenting Phase 1b/2a data at the #ADPD2026 meeting, Oryon Cell Therapies emerges from stealth mode with $42M & a focus on autologous neuron replacement therapies for #Parkinsons;
oryoncelltherapies.com/oryon-cell-t...
Great to have such good converations about DPUK at #ADPD2026. As Prof Sarah Bauermeister commented: "The high level of interest in our Data Portal and Trials Delivery Network showed how essential they are for human-based and translational research." zurl.co/iMiXv
💥Last week, several AD-RIDDLE partners were in Copenhagen for #ADPD2026.
📢 We’ve launched a new survey inviting healthcare professionals to share their experience with emerging #Alzheimers diagnostic tools⤵️
ad-riddle.org/frontline-ca...
That’s a wrap #ADPD2026!
In this 20th edition, the #BBRC contributed four oral presentations and two posters, reflecting the centre's broad research lines spanning biomarkers, proteomics, neuroimaging, and women's brain health. 👇
www.barcelonabeta.org/en/news/news...
Another great #adpd2026 meeting. Lots of excellent talks, networking and excitement in the field. Could not forget my @braincanada.bsky.social hat and
With #ADPD2026 drawing to a close, the discussions throughout the week have highlighted meaningful progress in treatments, diagnostics and prevention. We leave encouraged by the work shared in Copenhagen and the partnerships supporting progress across the dementia field.
🚀 It was an honor to present my latest research at #ADPD2026 in Copenhagen, where I discussed how #AI-enabled enrichment strategies can improve clinical trials in #Parkinson’s disease.
Clair Ashley presents her poster at the AD/PD Advances in Science & Therapy Conference.
Sierra Turner presents her poster at the AD/PD Advances in Science & Therapy Conference.
Riley Irmen presents during the AD/PD Advances in Science & Therapy Conference.
Sierra Turner, Riley Irmen, & Clair Ashley stand beside the canal in Nyhavn (New Harbour), Copenhagen, Denmark.
Shining bright at #ADPD2026! Members of the @macauleylab.bsky.social share their findings!
@ukresearch.bsky.social
Poster in a Short 🎥 Day 4
Ida Pesämaa explores how ferritin and FABP3 reveal an iron lipid axis in microglia, linking metabolism to Alzheimer’s disease mechanisms 👇 #ADPD2026 #Alzheimers
youtube.com/shorts/a0oTp...
#ADPD2026 Poster in a Short 🎥 Day 4
Gabriella Fiorino shows how boosting PINK1 activity improves mitochondrial function and neuronal resilience in Parkinson’s disease 👇 #Parkinsons
youtube.com/shorts/rxh9C...
Poster in a Short 🎥 Day 4
Hannah Macpherson @ukdri.ac.uk explores how the SNCA A53T variant shifts gene expression and transcript usage in Parkinson’s disease 👇 #ADPD2026 #Parkinsons
youtube.com/shorts/IGfl3...
Poster in a Short #ADPD2026 🎥 Day 4 - Can viral infection shape Parkinson’s biology? Priya Suman shows how virus exposure alters alpha synuclein signals and may connect immune activity to disease mechanisms 👇
youtube.com/shorts/uQWv8...
Online first @thelancet.com: the evoke and evoke+ randomised trials of semaglutide in early Alzheimer's disease #ADPD2026 www.thelancet.com/journals/lan...
Poster in a Short 🎥 Day 4
From marmosets to humans. Thais Rafael Guimaraes explores tau biology and disease pathways using ex vivo and cellular models 👇 #ADPD2026
youtube.com/shorts/crtrE...
Poster in a Short 🎥 Day 4
How does brain calcification affect structure? Paulina Mayer links imaging changes to volume loss and disease progression 👇 #ADPD2026
youtube.com/shorts/5XLhC...
In case you missed it at #ADPD2026: WDC member Phyllis Ferrell chaired the symposium “Blood Biomarkers: A Completed Chapter or Work in Progress? Practical Challenges and Solutions for Real‑World Implementation,” focused on advancing real‑world use of BBMs in Alzheimer’s disease.
Professor Johannes Attems, Professor of Neuropathology and member of the PSPA Research Committee chaired a session and presented at #ADPD2026 yesterday. His session was called ‘Linking Pathology and Biomarkers across Neurodegenerative #Disorders’ which looked at PSP & CBD. #MedicalConference
Poster in a Short 🎥 Day 4 at #ADPD2026 Bridging academia and real life care. Claire Webster develops education and resources to support caregivers and healthcare professionals in dementia 👇
youtube.com/shorts/SZzhK...
Live from #ADPD2026
Advancing Parkinson’s research by capturing real-time biochemical changes, in collaboration with @MichaelJFoxOrg.
Come by booth #01C to learn more!
In our April issue: a prospective cohort study investigating how plasma eMTBR-tau243 might be used together with p-tau217 to support Alzheimer's disease diagnosis and to predict tau tangle accumulation cognitive decline #ADPD2026 www.thelancet.com/journals/lan...
